These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 24529565

  • 1. Low bone mineral density is associated to poor glycemic control and increased OPG expression in children and adolescents with type 1 diabetes.
    Loureiro MB, Ururahy MA, Freire-Neto FP, Oliveira GH, Duarte VM, Luchessi AD, Brandão-Neto J, Hirata RD, Hirata MH, Maciel-Neto JJ, Arrais RF, Almeida MG, Rezende AA.
    Diabetes Res Clin Pract; 2014 Mar; 103(3):452-7. PubMed ID: 24529565
    [Abstract] [Full Text] [Related]

  • 2. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C, Gourgiotis D, Kossiva L, Doulgeraki A, Marmarinos A, Galli-Tsinopoulou A, Karavanaki K.
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [Abstract] [Full Text] [Related]

  • 3. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG, Kim JH, Kim JY, Ku SY, Jee BC, Suh CS, Kim SH, Choi YM.
    Menopause; 2007 Apr; 14(5):913-8. PubMed ID: 17667143
    [Abstract] [Full Text] [Related]

  • 4. OPG/RANK/RANKL signaling axis in patients with type I diabetes: Associations with parathormone and vitamin D.
    Karalazou P, Ntelios D, Chatzopoulou F, Fragou A, Taousani M, Mouzaki K, Galli-Tsinopoulou A, Kouidou S, Tzimagiorgis G.
    Ital J Pediatr; 2019 Dec 10; 45(1):161. PubMed ID: 31823791
    [Abstract] [Full Text] [Related]

  • 5. Gene-gene interactions in RANK/RANKL/OPG system influence bone mineral density in postmenopausal women.
    Zupan J, Mencej-Bedrac S, Jurković-Mlakar S, Prezelj J, Marc J.
    J Steroid Biochem Mol Biol; 2010 Jan 10; 118(1-2):102-6. PubMed ID: 19896533
    [Abstract] [Full Text] [Related]

  • 6. SERUM LEVELS OF FIBROBLAST GROWTH FACTOR-23, OSTEOPROTEGERIN, AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND IN PATIENTS WITH PROLACTINOMA.
    Arslan MS, Sahin M, Karakose M, Tutal E, Topaloglu O, Ucan B, Demirci T, Caliskan M, Ozdemir S, Ozbek M, Cakal E.
    Endocr Pract; 2017 Mar 10; 23(3):266-370. PubMed ID: 27849387
    [Abstract] [Full Text] [Related]

  • 7. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K, Perrea D, Doumouchtsis S, Tziamalis M, Poulakou M, Vlachos I, Kostakis A.
    Ther Apher Dial; 2009 Feb 10; 13(1):49-55. PubMed ID: 19379170
    [Abstract] [Full Text] [Related]

  • 8. Metabolic bone markers can be related to preserved insulin secretion in children with newly diagnosed type 1 diabetes.
    Szymańska M, Michałus I, Kaszkowiak M, Wyka K, Chlebna-Sokół D, Fendler W, Jakubowska-Pietkiewicz E, Młynarski W, Szadkowska A, Zmysłowska A.
    Pediatr Endocrinol Diabetes Metab; 2020 Feb 10; 26(1):10-16. PubMed ID: 32418417
    [Abstract] [Full Text] [Related]

  • 9. Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density.
    Tsentidis C, Gourgiotis D, Kossiva L, Marmarinos A, Doulgeraki A, Karavanaki K.
    Osteoporos Int; 2017 Mar 10; 28(3):945-953. PubMed ID: 27766367
    [Abstract] [Full Text] [Related]

  • 10. Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
    Stuss M, Rieske P, Cegłowska A, Stêpień-Kłos W, Liberski PP, Brzeziańska E, Sewerynek E.
    J Clin Endocrinol Metab; 2013 May 10; 98(5):E1007-11. PubMed ID: 23543663
    [Abstract] [Full Text] [Related]

  • 11. Relation of RANKL and OPG Levels with Bone Resorption in Patients with Acromegaly and Prolactinoma.
    Ozer FF, Dagdelen S, Erbas T.
    Horm Metab Res; 2018 Jul 10; 50(7):562-567. PubMed ID: 29895074
    [Abstract] [Full Text] [Related]

  • 12. Associations between bone, fat tissue and metabolic control in children and adolescents with type 1 diabetes mellitus.
    Wędrychowicz A, Stec M, Sztefko K, Starzyk JB.
    Exp Clin Endocrinol Diabetes; 2014 Sep 10; 122(8):491-5. PubMed ID: 24918536
    [Abstract] [Full Text] [Related]

  • 13. The Relationship between Serum and Gene Expression Levels of RANK, RANKL and Osteoprotegerin Inflammatory Pathway with Unstable Angina: A Case-control Study.
    Farrokhian A, Miraftab M, Chenari M, Akbari H, Nikoueinejad H, Naimi E.
    Iran J Allergy Asthma Immunol; 2021 Aug 07; 20(4):473-483. PubMed ID: 34418901
    [Abstract] [Full Text] [Related]

  • 14. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density.
    Suzuki K, Kurose T, Takizawa M, Maruyama M, Ushikawa K, Kikuyama M, Sugimoto C, Seino Y, Nagamatsu S, Ishida H.
    Diabetes Res Clin Pract; 2005 May 07; 68(2):117-25. PubMed ID: 15860239
    [Abstract] [Full Text] [Related]

  • 15. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
    Shaarawy M, Fathy SA, Mehany NL, Hindy OW.
    Clin Chem Lab Med; 2007 May 07; 45(11):1498-503. PubMed ID: 17970704
    [Abstract] [Full Text] [Related]

  • 16. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
    Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A.
    Osteoporos Int; 2006 May 07; 17(5):693-703. PubMed ID: 16435076
    [Abstract] [Full Text] [Related]

  • 17. Expression profile of osteoprotegerin, RANK and RANKL genes in the femoral head of patients with avascular necrosis.
    Samara S, Dailiana Z, Chassanidis C, Koromila T, Papatheodorou L, Malizos KN, Kollia P.
    Exp Mol Pathol; 2014 Feb 07; 96(1):9-14. PubMed ID: 24200492
    [Abstract] [Full Text] [Related]

  • 18. Bone turnover markers, osteoprotegerin and RANKL cytokines in children with cystic fibrosis.
    Ambroszkiewicz J, Sands D, Gajewska J, Chelchowska M, Laskowska-Klita T.
    Adv Med Sci; 2013 Feb 07; 58(2):338-43. PubMed ID: 24277958
    [Abstract] [Full Text] [Related]

  • 19. Mineral-bone metabolism markers in young hemodialysis patients.
    Osorio A, Ortega E, Torres JM, Sanchez P, Ruiz-Requena E.
    Clin Biochem; 2011 Dec 07; 44(17-18):1425-8. PubMed ID: 21933667
    [Abstract] [Full Text] [Related]

  • 20. Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms.
    Eid R, Abdelsalam M, Fathy AA, Abolenein HM, Elmarghany EB, El-Hanafy AA, Hamdy N, Abd-Elmagid DS, Niazy NA, Abd-El Ghaffar DM.
    Pediatr Rheumatol Online J; 2023 Jun 16; 21(1):58. PubMed ID: 37328895
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.